Wall Street Analysts Turn Bullish on 3 Promising Biotech Stocks (Buy Ratings)
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Analysts see big upside in UroGen, Rapport, and Milestone, driven by strong drugs, upcoming data, and underestimated market potential.
Milestone's (MIST) CARDAMYST nasal spray is FDA-approved for adults with PSVT (fast heart rate episodes). It's the first quick, self-administered home treatment.